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Purpose: Most patients with allergic rhinitis (AR) have moderate-to-severe disease, requir-
ing complete and prompt relief when symptoms occur. The time course of fluticasone
propionate (FP) penetration into nasal tissues after intranasal administration is not well
characterized. The goal of this proof-of-concept study was to evaluate the mucosal penetra-
tion of FP from fixed-combination FP-azelastine nasal spray (MP-AzeFlu) compared with an
FP-only nasal spray in an in vitro, 3-dimensional human bronchial tissue model.
Materials and Methods: Absorption of FP from MP-AzeFlu and FP nasal spray was
modeled using EpiAirway™606 (MatTek Corporation; Ashland, MA, USA) tissue cultured
in vertical diffusion cells. The dosing amount of MP-AzeFlu was optimized in a pilot study.
Based on the results of the pilot study, 10 µL of MP-AzeFlu (3.65 µg; n = 8) and 10 µL of FP
nasal spray (5.00 µg; n = 8) were evaluated for penetration of tissue. Tissue integrity was
monitored with Lucifer yellow. FP in the receiving media was quantified for each sample
using liquid chromatography with tandem mass spectrometry.
Results: MP-AzeFlu and FP nasal spray were associated with similar FP accumulation
profiles in the receiving media, but the permeability of FP was greater for MP-AzeFlu during
hours 0 to 6, suggesting faster absorption for MP-AzeFlu. No indications of compromised
tissue integrity were found in any of the tested cells.
Conclusion: The higher and more rapid penetration of FP from MP-AzeFlu supports the use
of MP-AzeFlu for patients with AR, particularly when prioritizing fast and pronounced
symptom relief.
Keywords: absorption, allergic rhinitis, azelastine hydrochloride, mucosal penetration,
pharmacology
Plain Language Summary
Most patients who have allergic rhinitis (AR) have a moderate-to-severe form of the disease.
Because of this, many of them consider it important to have fast, complete relief from their
symptoms. MP-AzeFlu, a nasal spray that contains a combination of azelastine hydrochloride
and fluticasone propionate (FP) and is dosed in a single spray, has been shown in studies to be
more effective than FP alone for treating patients with AR. The goal of this study was to
determine how much FP absorbs into the mucus membranes from MP-AzeFlu compared with
an FP-only nasal spray by using a lifelike model of human bronchial tissue. Using 10 µL of MP-
AzeFlu (3.65 µg; n = 8) and 10 µL of FP nasal spray (5.00 µg; n = 8), the researchers found that
although the 2 nasal sprays showed similar amounts of drug collected in the models, MP-AzeFlu
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absorbed into mucus membranes to a greater degree. This supports
findings from other clinical studies showing greater effectiveness of
MP-AzeFlu over FP-only nasal spray, as well as the use of MP-
AzeFlu to provide fast, complete symptom relief for patients
with AR.
Introduction
Most patients with allergic rhinitis (AR) have moderate-to-
severe disease. In a study of 3052 patients with AR, 93%
had moderate or severe disease on the basis of Allergic
Rhinitis and its Impact on Asthma classification.1 Because
of the severity of AR, many patients with AR prioritize
complete and prompt relief when symptoms occur. In
a study of adults with AR, patients reported they would
consider a treatment ineffective if it did not provide rapid
and long-lasting relief for their symptoms.2 Furthermore,
52% of patients reported they did not experience relief
within 1 hour when using intranasal corticosteroids for
AR.2 These data suggest a need for fast-acting, effective
treatments for AR symptom relief.
Intranasal fixed-combination azelastine hydrochloride
and fluticasone propionate (FP) delivered in a single
spray (MP-AzeFlu) has demonstrated superior efficacy to
intranasal FP (Flonase®) alone for treating AR. In a post
hoc analysis of a double-blind, placebo-controlled study of
people with moderate-to-severe AR, MP-AzeFlu resulted
in a significantly better improvement (52%) in the com-
bined total nasal and ocular symptom scores compared
with FP nasal spray alone.3 Even in people with severe
AR, MP-AzeFlu has been shown to provide relief for
individual nasal symptoms at levels greater than those
seen for FP alone.4
Despite patient reports of rapid relief, the time course of FP
penetration into nasal tissues after intranasal administration of
MP-AzeFlu or FP nasal spray alone is not well characterized.
To evaluate the mucosal penetration of FP from MP-AzeFlu,
an in vitro, 3-dimensional human bronchial tissue model was
used. This model has features associated with epithelial air-
ways, including a mixed-cell phenotype with ciliated, mucus-
secreting goblet and basal cells, as well as tight junctions.5
Primary human epithelial cell culturemodels have been shown
to be more sensitive to drug exposure than traditional immor-
talized cell culture models, and the permeable, 3-dimensional
nature facilitates penetration studies.5 The EpiAirway model
has been demonstrated to accurately assess drug permeability
of new intranasal drug formulations.6 The cells were mounted
in specially designed diffusion chambers to allow themeasure-
ment of drug absorption. We hypothesized that the enhanced
efficacy of MP-AzeFlu may be attributable to differences in
formulations between MP-AzeFlu and FP-only nasal spray.
Materials and Methods
Materials
MP-AzeFlu (0.1% solution azelastine hydrochloride and
0.037% suspension of micronized fluticasone propionate
in an isotonic aqueous suspension containing glycerin,
microcrystalline cellulose and carboxymethylcellulose
sodium, phenylethyl alcohol, edetate disodium, benzalko-
nium chloride, polysorbate 80, purified water) and FP
spray were obtained from the manufacturers. Other
reagents were obtained from commercial sources.
Study Design
EpiAirway™ EPI-606-X cells (MatTek Corporation;
Ashland, MA, USA) were cultured in vertical diffusion cells
at 37°C using 1-mL EpiAirway culture assay media (MatTek)
with 4% bovine serum albumin (Fisher Bioreagents;
Waltham, MA, USA). EpiAirway culture medium without
phenol red (MatTek) was used as receiving medium in the
bottom of the diffusion well.
The dosing amount of MP-AzeFlu was optimized in
a pilot study. As a result, 10 µL of MP-AzeFlu (3.65 µg;
n = 8) and 10 µL of FP (5.00 µg; n = 8) were evaluated for
penetration of epithelial tissue. MP-AzeFlu placebo nasal
spray was used as a control (n = 1).
MP-AzeFlu and FP-only formulations were applied
dropwise to the ciliated apical surface (top) of the
EpiAirway tissue. Samples were collected from the recei-
ver fluid in the bottom of the chamber at 1, 2, 4, 6, 18, and
18.5 hours to determine the extent of FP penetration
through the microporous membrane.
Tissue integrity was monitored with a Lucifer yellow
assay at 18 hours for all replicates and at 0 hours as
a control (n = 1). After the addition of 1.0 mL of 280
µM Lucifer yellow to each cell, the color change was
observed for 30 minutes to evaluate the tissue integrity.
After 30 minutes, 500 µL of receiving media was removed
with a glass syringe for analysis.
Analytic Methods
FP and Lucifer yellow in the receiving media were quanti-
fied for each sample using liquid chromatography with
tandem mass spectrometry (LC-MS/MS). Chromatographic
separation was performed with a Waters XBridge C18
Column (Waters Corporation, Milford, MA, USA; 3.0 mm
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x 50 mm, 3.5 µm) on a Shimadzu LC system with an LC-
20AD pump and an SIL-20AC/HT autosampler (Shimadzu
Scientific Instruments; Kyoto, Japan). The mobile phase
consisted of (A) 0.1% formic acid in water and (B) 0.1%
formic acid in acetonitrile. The linear gradient elution pro-
gram was as follows: 0.01 min, 95% A; 0.17 min, 95% A;
2.50 min, 0% A; 4.00 min, 0% A; 4.10 min, 95% A; and
5.00 min, 0% A. The flow rate was 0.5 mL/min, and the total
run time was 5.0 min. MS was performed with an API 4000
(SCIEX; Framingham, MA, USA) and a TurboIonSpray
interface (SCIEX) with a dwell time of 50 ms at
a temperature of 700°C.
The parameters calculated based on the LC-MS/MS
penetration profile were amounts of FP in receiver media
(ng/cm2), flux of FP (ng/cm2/h), permeability of FP (nm/
s), and Lucifer yellow tissue integrity.
Results
MP-AzeFlu and FP nasal spray were associated with similar
FP accumulation profiles in the receivingmedia (Figure 1). On
the basis of theoretical calculations, the drug accumulation
profiles were suggestive of 2.5% drug delivery. However,
because the concentration of FP differs between MP-AzeFlu
and FP nasal spray, the permeability value differed despite the
similar accumulation profiles.MP-AzeFlu placebo and the no-
treatment control did not result in FP in the receiving media.
After controlling for differences in the concentration of
FP in each product, FP flux and permeability were similar
between MP-AzeFlu and FP nasal spray at 18 hours.
Between 0 and 6 hours, MP-AzeFlu resulted in signifi-
cantly higher FP penetration than FP nasal spray
(P <0.05). Permeability profiles are shown in Figure 2.
No indications of compromised tissue integrity were
observed in any of the tested cells. The drug concentration
in the receiving media increased gradually over the time
points evaluated, suggesting maintenance of tissue integ-
rity. Lucifer yellow content was uniform in all the cells at
18.5 hours, similar to the content reported for the control
well at time point 0 hours, providing additional support for
the maintenance of tissue integrity (Figure 3).
Discussion
In this proof-of-concept study utilizing a 3-dimensional
model of airway tissue, the application of both MP-AzeFlu
and FP nasal spray resulted in FP penetration of the micro-
porous membrane. This in vitro studywas the first to evaluate
the effect of the formulation on the penetration of only FP.
Absolute amounts of accumulated FP were similar between
treatments, but FP permeation occurred more quickly with
MP-AzeFlu than with FP nasal spray. This would suggest
that, compared with use of FP nasal spray, use of MP-AzeFlu
may result in faster penetration of local nasal tissue, allowing
Figure 1 Mean amount of fluticasone propionate released in receiving media (average of 8 cells + SD).
Abbreviations: API, active pharmaceutical ingredient; FP, fluticasone propionate; h, hour; MP-AzeFlu, combination FP-azelastine nasal spray; SD, standard deviation; T, time point.
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for quicker local effects. These results are clinically impor-
tant, because active ingredients of intranasal medications are
removed from the nasal cavity by mucociliary clearance in
a time-dependent manner.7
The results reported here are consistent with the findings
from prior pharmacokinetic (PK) studies, as well as from
a clinical trial comparing the onset of action of MP-AzeFlu
and commercially available FP nasal spray.8,9 In the PK study,
Figure 2 Permeability profiles of MP-AzeFlu and fluticasone propionate nasal spray (average of 8 cells + SD).
Abbreviations: FP, fluticasone propionate; h, hour; MP-AzeFlu, combination FP-azelastine nasal spray; SD, standard deviation.
Figure 3 Tissue integrity on the basis of Lucifer yellow testing after 18 hours.
Abbreviations: C, cell; h, hour; T, time.
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the maximum and total FP exposure among participants was
60% higher for MP-AzeFlu than for FP nasal spray despite
their receiving the same nominal dose. However, MP-AzeFlu
demonstrated limited systemic FP bioavailability (1.86%) and
mean peak FP concentration of 10–12 pg/mL or less, well
below the systemic concentrations that are likely to have
clinical effects.8 Nasal delivery of the medication directly to
the local site of action avoids clinically significant systemic
corticosteroid exposure.8 In a randomized, controlled trial, AR
symptoms were induced by exposure to ragweed pollen in an
environmental exposure chamber. A single dose of MP-
AzeFlu was associated with a significantly faster onset of
action than the free combination of intranasal FP and oral
loratadine (5 vs 150 minutes); however, differences in rates
of absorption for FP may be attributable to the faster effect of
intranasal versus oral antihistamines.9 Of note, the maximum
approved daily dose for FP products (400 µg) is twice the
intended daily dose of MP-AzeFlu (200 µg).10 Therefore,
with regular use of MP-AzeFlu, patients will be exposed to
less overall FP than with commercially available FP mono-
therapy products that have been established as safe.
Several potential explanations exist for the higher level
of permeation of FP from MP-AzeFlu formulation com-
pared with conventional FP nasal spray. The formulations
of the products are different, which could lead to different
solubilities of FP. Whereas both products contain FP as
suspensions, MP-AzeFlu also contains azelastine in solu-
tion. It is possible that the differing formulation may lead to
dissolution of FP to a greater extent in MP-AzeFlu than in
FP nasal spray. The presence of a concomitant drug in the
product may affect mucosal permeability and it is possible
that azelastine acts as an absorption enhancer. Furthermore,
excipients, including EDTA-Na2 (potential penetration
enhancer, not present in conventional FP nasal spray) and
lower concentration of benzalkonium chloride, may also
contribute to the greater permeability of FP in MP-
AzeFlu. While this study was not intended to evaluate the
effect of different excipients on the level of permeation of
FP into nasal tissues, given these results, future studies
evaluating their effects would provide further insight into
their potential impact. Finally, differences in droplet size
distribution and spray pattern may influence the penetration
of FP in vivo, and the difference in viscosity may influence
the penetration of FP in vitro and in vivo.
Conclusions
Small differences in formulations may matter, and FP from
MP-AzeFlu penetrated epithelial tissue in vitro more quickly
than FP from conventional nasal spray. The higher and more
rapid penetration of FP fromMP-AzeFlu in these experiments
provides support for observations made in clinical studies and
for the use of MP-AzeFlu in patients with AR, particularly
when prioritizing fast and pronounced symptom relief.
Abbreviations
AR, allergic rhinitis; FP, fluticasone propionate; LC-MS
/MS, liquid chromatography with tandem mass spectro-
metry; PK, pharmacokinetic.
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